- Home
- ANL vs ALT Comparison
ANL vs ALT Comparison
Compare ANL & ALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ANL | ALT |
|---|---|---|
| Founded | 2004 | 1997 |
| Country | Cayman Islands | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 406.5M | 421.5M |
| IPO Year | 2022 | 2005 |
Fundamental Metrics
Financial Performance| Metric | ANL | ALT |
|---|---|---|
| Price | $15.68 | $3.35 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | $16.00 | ★ $17.67 |
| AVG Volume (30 Days) | 350.7K | ★ 2.6M |
| Earning Date | 04-20-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 25.37 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $41,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 105.00 |
| 52 Week Low | $0.88 | $2.87 |
| 52 Week High | $13.00 | $7.73 |
Technical Indicators
Market Signals| Indicator | ANL | ALT |
|---|---|---|
| Relative Strength Index (RSI) | 80.26 | 42.47 |
| Support Level | $1.36 | $2.87 |
| Resistance Level | N/A | $4.25 |
| Average True Range (ATR) | 1.38 | 0.16 |
| MACD | 0.70 | 0.05 |
| Stochastic Oscillator | 99.31 | 60.45 |
Price Performance
Historical ComparisonAbout ANL Adlai Nortye Ltd.
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.
About ALT Altimmune Inc.
Altimmune Inc is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. The Company's key candidate, pemvidutide, is a dual-action therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.